证券代码：300633 证券简称：开立医疗 公告编号：2023-060 深圳开立生物医疗科技股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2023 年 11 月 7 日，深圳开立生物医疗科技股份有限公司（以下简称"公司"） 第三届董事会第十六次会议以现场和通讯表决相结合的方式在深圳市光明区光 电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2023 年 10 月 31 日 以电话、电子邮件等方式通知全体董事。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： （一）逐项审议通过了《关于回购公司股份方案的议案》 公司实际控制人陈志强先生和吴坤祥先生提议公司使用自有资金以集中竞 价交易方式回购公司已发行的部分人民币普通股（A 股）股票，根据《公司法》、 《证券法》、《上市公司股份回购规则》、《深 ...

深圳开立生物医疗科技股份有限公司 关于收到公司实际控制人提议回购公司股份的提示性公告 证券代码：300633 证券简称：开立医疗 公告编号：2023-058 公司实际控制人陈志强先生、吴坤祥先生保证向本公司提供的信息内容真 实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）于近日收到公 司实际控制人陈志强先生和吴坤祥先生（一致行动人）出具的《关于提议公司 回购股份的函》，具体内容主要如下： 一、提议人的基本情况及提议时间 1、提议人：公司实际控制人陈志强先生和吴坤祥先生（一致行动人） 2、提议时间：2023 年 10 月 29 日 二、提议回购股份的原因和目的 基于对公司未来发展的信心和对公司价值的高度认可，为有效增强投资者信 心，同时，为进一步健全公司激励机制，提升团队凝聚力和企业竞争力，促进公 司健康可持续发展，公司实际控制人陈志强先生和吴坤祥先生提议公司使用自有 资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，并 在未来适宜时机用于股权激励或员工持股计划。 三 ...

Financial Performance - In the first three quarters of 2023, the company achieved a revenue of 1.468 billion, representing a year-on-year growth of 17.31% [2] - Net profit for the same period was 321 million, with a year-on-year increase of 30.65%, maintaining a profit growth rate higher than revenue growth [2] - The third quarter saw stable revenue due to external environmental factors, while expenses increased due to surgical team and travel costs, leading to a slight decline in net profit [2] Product Development - The HD-580 series endoscope is a significant upgrade from the HD-550, featuring enhanced image quality, contrast, signal-to-noise ratio, and electronic staining algorithms [3] - The new model supports advanced imaging modes and has improved light sensitivity and response time, positioning it for a higher market segment compared to the HD-550 [3] Market Outlook - The company anticipates a recovery in the fourth quarter due to traditional seasonal demand, with expectations of improved sales as external factors stabilize [3] - The ultrasound business faced challenges in Q3 due to market saturation, while the endoscope segment continued to grow at a high rate [3] - The company believes that the industry environment will favor leading brands, enhancing their competitive position in the market [3] International Business - The company has a stable overseas sales presence in nearly 130 countries, with significant sales in Europe and South America [4] - The overseas business is expected to continue stable growth, supported by the establishment of marketing subsidiaries in countries like India, the Netherlands, Russia, and Germany [4]

证券代码：300633 证券简称：开立医疗 公告编号：2023-057 深圳开立生物医疗科技股份有限公司 关于控股股东、董事、高级管理人员承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）近日收到公司 控股股东、实际控制人陈志强先生和吴坤祥先生（一致行动人），持有公司股份 的董事兼高级管理人员黄奕波先生、周文平先生，高级管理人员李浩先生出具 的《关于自愿承诺不减持公司股份的承诺函》，具体内容如下： 一、承诺的主要内容 基于对公司未来发展和持续经营的信心及价值判断，为维护资本市场稳 定，维护广大投资者利益： 1、公司控股股东、实际控制人陈志强先生和吴坤祥先生（一致行动人）自 愿承诺：自 2023 年 10 月 27 日起至 2024 年 10 月 26 日（自承诺之日起 12 个月） 期间不减持其所持有的公司股份，如因公司资本公积转增股本、派送股票红利等 情况而增加股份的，增加的股份亦遵守上述股份锁定安排。 2、持有公司股份的董事兼高级管理人员黄奕波先生、周文平先生，高级管 理人员李浩先 ...

Financial Performance - The company's revenue for Q3 2023 was ¥424,493,439.43, representing a 2.10% increase year-over-year, while the year-to-date revenue reached ¥1,467,832,830.33, up 17.31% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥47,557,302.30, a decrease of 32.60% year-over-year, with a year-to-date net profit of ¥320,617,148.08, which is an increase of 30.65% compared to the previous year[4] - The basic earnings per share for Q3 2023 was ¥0.1104, down 33.05% year-over-year, while the diluted earnings per share was ¥0.1099, a decrease of 33.35% compared to the same period last year[4] - Total operating revenue for the third quarter reached ¥1,467,832,830.33, an increase of 17.3% compared to ¥1,251,288,639.90 in the same period last year[19] - Net profit attributable to shareholders of the parent company was ¥320,617,148.08, up 30.6% from ¥245,400,442.53 in the previous year[20] - Total comprehensive income for the period was ¥327,829,831.42, compared to ¥262,080,081.04 in the previous year, reflecting a growth of 25.2%[21] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥3,713,422,646.06, reflecting a 4.77% increase from the end of the previous year, and total equity attributable to shareholders was ¥3,059,335,673.46, up 11.66% year-over-year[4] - As of September 30, 2023, the company's total assets amounted to CNY 3,713,422,646.06, an increase from CNY 3,544,216,145.59 at the beginning of the year[16] - The company's total liabilities decreased to CNY 599,923,910.88 from CNY 749,417,628.27, indicating a reduction of approximately 20%[17] - Total liabilities decreased to ¥654,086,972.60 from ¥804,413,526.41, reflecting a reduction of approximately 18.6%[20] - The company's total equity increased to ¥3,059,335,673.46, up from ¥2,739,802,619.18, marking a growth of 11.6%[20] Cash Flow - The company reported a net cash flow from operating activities of ¥241,152,545.82 year-to-date, which is a slight increase of 1.82% compared to the same period last year[4] - Cash flow from operating activities was ¥1,670,441,243.62, compared to ¥1,502,946,577.00 in the previous year, indicating a growth of 11.2%[22] - The net cash flow from operating activities for Q3 2023 was CNY 241,152,545.82, slightly up from CNY 236,843,233.58 in Q3 2022, indicating a growth of approximately 1.3%[23] - Total cash outflow from operating activities amounted to CNY 1,429,288,697.80, compared to CNY 1,266,103,343.42 in the same period last year, representing an increase of about 12.9%[23] - The net cash flow from investing activities was CNY 168,460,761.85, a significant improvement from a negative CNY 411,200,739.01 in Q3 2022[23] - The net cash flow from financing activities was negative CNY 129,270,293.90, worsening from negative CNY 28,649,525.54 in Q3 2022[23] Investments and Expenses - Research and development expenses amounted to ¥263,619,138.72, representing an increase of 8.5% from ¥242,758,050.85 in the previous year[20] - The company reported a decrease in cash paid for other investment activities, amounting to ¥1,655,000,000, a significant drop of 82.51% year-over-year, attributed to reduced cash outflow for financial product purchases[9] - The company experienced a significant decrease in trading financial assets, with a year-end balance of ¥109,139,800, a reduction of 73.98% from the beginning of the year due to decreased investment in financial products[8] Shareholder Information - The company has a significant shareholder structure, with the top two shareholders, Chen Zhiqiang and Wu Kunxiang, each holding 22.23% of the shares[11] - The company issued 3,294,000 restricted stock units to 34 incentive targets in September 2023 to promote the rapid development of its minimally invasive surgical business[14] Taxation - The company’s tax and additional charges for the year-to-date were ¥18,203,200, an increase of 69.96% year-over-year, primarily due to increased revenue leading to higher additional taxes[9] - The company received software revenue tax refunds amounting to ¥59,307,306.16, which is considered a regular income due to its close relation to the company's main business operations[7] - The company reported a cash and cash equivalents net increase of CNY 278,170,036.40, contrasting with a decrease of CNY 198,427,604.27 in Q3 2022[23] - The company’s total tax payments rose to CNY 134,671,766.21 from CNY 109,909,065.56, reflecting an increase of approximately 22.5%[23] Growth Strategy - The company plans to expand its market presence and invest in new product development as part of its growth strategy[14]

证券代码：300633 证券简称：开立医疗 公告编号：2023-055 深圳开立生物医疗科技股份有限公司 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2023 年 10 月 24 日，深圳开立生物医疗科技股份有限公司（以下简称"公 司"）第三届董事会第十五次会议以现场和通讯表决相结合的方式在深圳市光明 区光电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2023 年 10 月 17 日以电话、电子邮件等方式通知全体董事。 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于公司<2023 年第三季度报告>的议案》 经审议，董事会一致认为：公司 2023 年第三季度报告真实反映了公司 2023 年前三季度的财务状况和经营成果，符合法律、行政法规、中国证监会和深圳证 券交易所的相关规定，报告内容真实、准确，完整，不存在任何虚假记载、误导 性陈述或者重大遗漏，同意公司对外报出。 具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）上披露 ...

证券代码：300633 证券简称：开立医疗 公告编号：2023-056 经审核，监事会认为董事会编制和审核的公司 2023 年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）上披露的《2023 年第三季度报告》。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 深圳开立生物医疗科技股份有限公司 第三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2023 年 10 月 24 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第三届监事会第十五次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 ...

Group 1: Company Overview - The participating units include Abu Dhabi Investment Authority, Hongtu Innovation Fund, Invesco Great Wall, Baoying Fund, and Guoyuan Securities [1] - The company is Shenzhen Kaili Biomedical Technology Co., Ltd. [4] Group 2: Investor Relations Activities - The investor relations activities took place from September 25 to 27, 2023, in the company meeting room [3] - The activities included analyst meetings, media interviews, performance briefings, press releases, roadshows, site visits, one-on-one communications, and conference calls [2] Group 3: Product Performance and Market Position - The HD-550 series has seen significant growth in sales revenue, with an increased number of multi-scope working machines in clinical settings [3] - The company has adjusted its internal sales assessment mechanism to enhance the importance of installation data in sales personnel performance [3] - The market share of the company's digestive endoscopes has surpassed some imported brands, with products recognized in over 300 tertiary hospitals in China [5] Group 4: Product Development and Upgrades - The new HD-580 series represents a significant upgrade over the HD-550, featuring improved image quality, contrast, signal-to-noise ratio, and electronic staining algorithms [5] - The company aims to continuously invest a high percentage of its revenue in R&D to address gaps in product lifespan and high-end functionalities compared to imported brands [5]

Group 1: Investor Relations Activities - The investor relations activities took place from September 19 to 21, 2023, involving various types of engagements such as analyst meetings and one-on-one communications [2] - Participating institutions included CITIC Securities, Guotai Junan, and several investment funds [2] Group 2: Market Impact and Company Performance - The company indicated that the ongoing medical anti-corruption efforts have led to a temporary slowdown in market activities, including reduced frequency of academic meetings and some tender delays [2] - Despite short-term pressures, the company believes that the long-term outlook for the medical equipment market remains positive, with a focus on companies with technological and product advantages [2] Group 3: Product Competitive Advantages - The company has strong competitive advantages in its endoscope products, including advanced 2K and 4K white light hard endoscopes, and has received certifications for new generation products [3] - A newly introduced foreign marketing team with extensive surgical experience is expected to enhance the company's surgical business development [3] - The company aims to provide comprehensive surgical solutions by leveraging successful experiences from imported brands and its existing ultrasound and flexible endoscope products [3] Group 4: Ultrasound Business and Profit Margins - The gross margin of the ultrasound business has remained stable over the past few years, positioned relatively high within the industry due to significant R&D investments [3] - The company launched a new high-end ultrasound platform, the S90 Exp series, which includes advanced features and is expected to improve the gross margin as the proportion of high-end products increases [3]

证券代码：300633 证券简称：开立医疗 公告编号：2023-051 深圳开立生物医疗科技股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2023 年 9 月 20 日，深圳开立生物医疗科技股份有限公司（以下简称"公司"） 第三届董事会第十四次会议以现场和通讯表决相结合的方式在深圳市光明区光 电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2023 年 9 月 11 日以 电话、电子邮件等方式通知全体董事。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： 三、备查文件 1、第三届董事会第十四次会议决议。 特此公告。 深圳开立生物医疗科技股份有限公司董事会 2023 年 9 月 21 日 1、审议通过《关于向激励对象授予限制性股票的议案》 根据《上市公司股权激励管理办法》、公司《2023 年 ...